title: An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists.
abstract: Among the agents classified as "Category A" by the U.S. Centers for Disease Control and Prevention, botulinum neurotoxin (BoNT) is the most toxic protein known, with microgram quantities of the protein causing severe morbidity and mortality by oral or i.v. routes. Given that this toxin easily could be used in a potential bioterrorist attack, countermeasures urgently are needed to counteract the pathophysiology of BoNT. At a molecular level, BoNT exerts its paralytic effects through intracellular cleavage of vesicle docking proteins and subsequent organism-wide autonomic dysfunction. In an effort to identify small molecules that would disrupt the interaction between the light-chain metalloprotease of BoNT serotype A and its cognate substrate, a multifaceted screening effort was undertaken. Through the combination of in vitro screening against an optimized variant of the light chain involving kinetic analysis, cellular protection assays, and in vivo mouse toxicity assays, molecules that prevent BoNT/A-induced intracellular substrate cleavage and extend the time to death of animals challenged with lethal toxin doses were identified. Significantly, the two most efficacious compounds in vivo showed less effective activity in cellular assays intended to mimic BoNT exposure; indeed, one of these compounds was cytotoxic at concentrations three orders of magnitude below its effective dose in animals. These two lead compounds have surprisingly simple molecular structures and are readily amenable to optimization efforts for improvements in their biological activity. The findings validate the use of high-throughput screening protocols to define previously unrecognized chemical scaffolds for the development of therapeutic agents to treat BoNT exposure.
authors.affiliation: Department of Chemistry, The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA.
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Eubanks
authors.forename: Mark S
authors.initials: MS
authors.lastname: Hixon
authors.forename: Wei
authors.initials: W
authors.lastname: Jin
authors.forename: Sukwon
authors.initials: S
authors.lastname: Hong
authors.forename: Colin M
authors.initials: CM
authors.lastname: Clancy
authors.forename: William H
authors.initials: WH
authors.lastname: Tepp
authors.forename: Michael R
authors.initials: MR
authors.lastname: Baldwin
authors.forename: Carl J
authors.initials: CJ
authors.lastname: Malizio
authors.forename: Michael C
authors.initials: MC
authors.lastname: Goodnough
authors.forename: Joseph T
authors.initials: JT
authors.lastname: Barbieri
authors.forename: Eric A
authors.initials: EA
authors.lastname: Johnson
authors.forename: Dale L
authors.initials: DL
authors.lastname: Boger
authors.forename: Tobin J
authors.initials: TJ
authors.lastname: Dickerson
authors.forename: Kim D
authors.initials: KD
authors.lastname: Janda
mesh_terms: D000818:Animals; D019274:Botulinum Toxins, Type A / Q000037:antagonists & inhibitors*; D005260:Female; D020128:Inhibitory Concentration 50; D051379:Mice; D009465:Neuromuscular Agents / Q000032:analysis* / Q000737:chemistry / Q000494:pharmacology*; D050825:Synaptosomal-Associated Protein 25 / Q000378:metabolism
chemical_list: D009465:Neuromuscular Agents; D050825:Synaptosomal-Associated Protein 25; D019274:Botulinum Toxins, Type A